A CLINICAL RESEARCH CAREER WORKING SPONSOR-SIDE, CRO-SIDE TO SITE-SIDE AT PARATUS CLINICAL
With
Megan Morrison,
Chief Executive Officer
Paratus Clinical
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | December 2025
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
Megan Morrison as the Chief Executive Officer of Paratus Clinical, brings more than 24 years of experience in the clinical research industry. She has held senior leadership roles across sponsor organisations, CROs and clinical sites, giving her a uniquely comprehensive perspective on the challenges and opportunities across the drug development ecosystem.
With a background in pharmacology and a Master of Business Administration, Megan combines scientific expertise with commercial and operational acumen. She is committed to advancing Australia’s role in global clinical research by expanding access to innovative studies, strengthening partnerships with sponsors, and ensuring that high-quality outcomes are delivered for both patients and partners.
In this interview with Australian Health Journal she talks about her career journey, current trends in the industry as well as recent projects. Megan also shares her career advice on being curious, in a frequently changing environment such as clinical research, for the benefit of sponsors getting new therapies to market.
Source: Adapted from Paratus Clinical media releases and website
-
Stroke care advances in translated research
New nurse-led protocols for stroke patients, based on ACU research, led by the Nursing Research Institute, have resulted in changes to policy, guidelines and clinical practice in Europe and Australia. The protocols were developed through the Quality in Acute Stroke Care (QASC) Trial (published in the Lancet, 2011) to manage fever, hyperglycaemia and swallowing (FeSS) post-stroke.
-
Priming Australia for social prescribing
Social prescribing provides support in various areas of people’s lives, leading to increased confidence, improved navigation of systems, and enhanced friendships and trust in healthcare, while communities should be designed in an age-friendly way to prevent isolation.
In Part 1 of the Models of Care on Social Prescribing, Australian Health Journal spoke to 4 people advocating for social prescribing in Australia
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
